Kite and Humanigen link up to trial Yescarta with lenzilumab

31 May 2019

Shares of Humanigen (OTCMKTS: HGEN) rose 8.7% to $1.24 by mid-morning today, after it revealed a clinical collaboration with Gilead Sciences’ (Nasdaq: GILD) subsidiary Kite to trial a combination of its flagship therapy in combination with one of the first CAR-T cell therapy to be approved by the US regulator.

The companies will conduct a Phase I/II study of Humanigen’s lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Kite’s Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta.

Kite will act as the sponsor of this study and will be responsible for its conduct, while Humanigen will supply its product. No financial terms of the collaboration have been revealed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK